CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhIL-15) is associated with expansion of peripheral blood CD56+ NK cells and CD8+ T cells

समान संसाधन

• CITN11-02 interim trial results: subcutaneous administration of recombinant human IL-15 (rhil-15) is associated with robust expansion of peripheral blood CD56+ NK cells
  द्वारा: Morishima, Chihiro, और अन्य
  प्रकाशित: (2014)
• A First-in-Human Phase 1 Study of Subcutaneous Outpatient Recombinant Human IL-15 (rhIL-15) in Adults with Advanced Solid Tumors
  द्वारा: Miller, Jeffrey S., और अन्य
  प्रकाशित: (2017)
• CITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
  द्वारा: Margolin, Kim, और अन्य
  प्रकाशित: (2014)
• First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia
  द्वारा: Cooley, Sarah, और अन्य
  प्रकाशित: (2019)
• Combination rhIL-15 and Anti-PD-L1 (Avelumab) Enhances HIVGag-Specific CD8 T-Cell Function
  द्वारा: Goshu, Bruktawit A, और अन्य
  प्रकाशित: (2020)